Search Results

You are looking at 1 - 10 of 61 items for :

  • "peptide receptor radionuclide therapy (PRRT)" x
  • Refine by Access: Content accessible to me x
Clear All
Free access

Tessa Brabander, Wouter A van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, Richard A Feelders, Eric P Krenning, and Dik J Kwekkeboom

time of presentation ( Korse et al . 2013 ). In the past decade a promising new treatment modality has been developed for inoperable or metastasized NETs. This peptide receptor radionuclide therapy (PRRT) uses radiolabeled somatostatin analogues. Since

Free access

Mintallah Haider, Satya Das, Taymeyah Al-Toubah, Eleonora Pelle, Ghassan El-Haddad, and Jonathan Strosberg

, Remes et al. 2019 ). An emerging class of therapeutics for patients with WD NETs consists of radiolabeled somatostatin analogs (SSA), which fall under the broader therapeutic class of peptide receptor radionuclide therapy (PRRT). PRRT enables the

Free access

Tessa Brabander, Julie Nonnekens, and Johannes Hofland

radionuclide therapy (PRRT) ( Kwekkeboom et al. 2005 ). This was successfully implemented for [ 90 Y]Y-DOTA-[Tyr3]octreotide ( 90 Y-DOTATOC) and [ 177 Lu]Lu-DOTA-[Tyr3]octreotate ( 177 Lu-DOTATATE), with the latter radioligand now registered for therapy of

Free access

Lisa Bodei, Irvin M Modlin, Markus Luster, Flavio Forrer, Marta Cremonesi, Rodney J Hicks, Samer Ezziddin, Mark Kidd, and Arturo Chiti

Introduction It is now widely accepted that peptide receptor radionuclide therapy (PRRT) is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic (GEP) or

Free access

Cecile N Chougnet, Sophie Leboulleux, Caroline Caramella, Jean Lumbroso, Isabelle Borget, Désirée Déandreis, Pierre Duvillard, Dominique Elias, Thierry de Baere, Fritz-Line Vélayoudom-Céphise, Joël Guigay, Michel Ducreux, Martin Schlumberger, and Eric Baudin

tomography (PET)-dedicated tracers ( Ambrosini et al . 2008 , Srirajaskanthan et al . 2010 ) and the use of tracers with higher affinity for sstr ( Krenning et al . 1999 , Carrasquillo & Chen 2010 ). Peptide receptor radionuclide therapy (PRRT) that uses

Free access

Wouter T Zandee, Kimberly Kamp, Roxanne C van Adrichem, Richard A Feelders, and Wouter W de Herder

times daily for octreotide subcutaneously, once more improving quality of life for patients ( Rinke et al . 2009 , Caplin et al . 2014 ). Also peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs and tumor

Free access

Halfdan Sorbye, Grace Kong, and Simona Grozinsky-Glasberg

Background Peptide receptor radionuclide therapy (PRRT) Peptide receptor radionuclide therapy (PRRT) delivers highly localized radiation by targeting specific peptide receptors on tumor cells ( Hicks et al . 2017 ). This therapy has been

Free access

David A Pattison and Rodney J Hicks

in patients deemed otherwise suitable for peptide receptor radionuclide therapy (PRRT). Figure 1 Molecular targets currently utilised for imaging and radionuclide therapy of insulinoma. Adapted from Trends in Endocrinology & Metabolism , Vol

Free access

Esben Andreas Carlsen, Nicola Fazio, Dan Granberg, Simona Grozinsky-Glasberg, Hojjat Ahmadzadehfar, Chiara Maria Grana, Wouter T Zandee, Jaroslaw Cwikla, Martin A Walter, Peter Sandor Oturai, Anja Rinke, Andrew Weaver, Andrea Frilling, Sara Gritti, Anne Kirstine Arveschoug, Amichay Meirovitz, Ulrich Knigge, and Halfdan Sorbye

, Yamaguchi et al . 2014 , Heetfeld et al . 2015 , Walter et al . 2017 ). In metastatic GEP NET G1–G2, peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors has been used with excellent results for the last two decades in Europe

Free access

Jaap J M Teunissen, Dik J Kwekkeboom, R Valkema, and Eric P Krenning

patients who had inoperable and/or metastasised NETs. Therefore, the first peptide receptor radionuclide therapy (PRRT) was performed with high administered activity of [ 111 In-DTPA 0 ]octreotide ( Krenning et al . 1994 a ). However, besides encouraging